caa a22 4500 465737765 CHVBK 20180323111759.0 cr unu---uuuuu 170327e19900501xx s 000 0 eng 10.1007/BF02253719 doi (NATIONALLICENCE)springer-10.1007/BF02253719 Effects of single and repeated treatment with antidepressants on apomorphine-induced yawning in the rat: the implication of α-1 adrenergic mechanisms in the d -2 receptor function [Elektronische Daten] [A. Delini-Stula, C. Hunn] Acute (10 or 20 mg/kg IP) and subchronic (2 × 5 or 10 mg/kg IP daily for 7 days) effects of desipramine, imipramine, maprotiline, (+)- and (−)-oxaprotiline enantiomers as well as selective 5-HT-uptake inhibitors citalopram and ifoxetine on yawning, induced by low doses of apomorphine, were investigated in the rat. In addition, the effects of α-1 receptor agonist adrafinil and antagonist prazosin were also tested. After acute treatment, desipramine, the stereoselective NA-uptake inhibiting (+)-enantiomer of oxaprotiline, and the α-1 agonist adrafinil, markedly and significantly suppressed yawning. Prazosin, in contrast, clearly potentiated it. This potentiating effect was abolished by the pretreatment with (+)-oxaprotiline and adrafinil. Other drugs were inactive. After subchronic administration, yawning was antagonized by NA-uptake-inhibiting antidepressants, including imipramine and maprotiline. By comparison to the acute treatment, the inhibitory effects of desipramine and (+)-oxaprotiline were considerably enhanced. Neither selective 5-HT-uptake inhibitors nor (−)-oxaprotiline (levoprotiline) were active. Antidepressants therefore modulate the functional activity of D-2 receptors, activated by low doses of apomorphine, predominantly by the virtue of their noradrenergic enhancing properties. This modulatory effect appears to be mediated by α-1 adrenergic receptors. Springer-Verlag, 1990 Antidepressants nationallicence Yawning nationallicence D-2 receptors nationallicence Adrafinil nationallicence Apomorphine nationallicence Oxaprotiline nationallicence Levoprotiline nationallicence Chronic treatment nationallicence α-1 receptors nationallicence Delini-Stula A. Research Laboratories, Pharmaceuticals Division, CIBA-GEIGY Ltd., K125/1549, CH-4002, Basle, Switzerland aut Hunn C. Research Laboratories, Pharmaceuticals Division, CIBA-GEIGY Ltd., K125/1549, CH-4002, Basle, Switzerland aut Psychopharmacology Springer-Verlag 101/1(1990-05-01), 62-66 0033-3158 101:1<62 1990 101 213 https://doi.org/10.1007/BF02253719 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02253719 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Delini-Stula A. Research Laboratories, Pharmaceuticals Division, CIBA-GEIGY Ltd., K125/1549, CH-4002, Basle, Switzerland aut NATIONALLICENCE 700 1- Hunn C. Research Laboratories, Pharmaceuticals Division, CIBA-GEIGY Ltd., K125/1549, CH-4002, Basle, Switzerland aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 101/1(1990-05-01), 62-66 0033-3158 101:1<62 1990 101 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer